Compare ARQT & THO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | THO |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2020 | 1994 |
| Metric | ARQT | THO |
|---|---|---|
| Price | $28.05 | $76.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $34.00 | ★ $111.75 |
| AVG Volume (30 Days) | ★ 1.7M | 758.3K |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | N/A | ★ 2.67% |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ 2.59 |
| Revenue | $376,072,000.00 | ★ $9,579,490,000.00 |
| Revenue This Year | $34.85 | $1.21 |
| Revenue Next Year | $29.39 | $5.17 |
| P/E Ratio | ★ N/A | $29.18 |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $13.70 | $69.71 |
| 52 Week High | $31.77 | $122.83 |
| Indicator | ARQT | THO |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 51.41 |
| Support Level | $27.63 | $74.45 |
| Resistance Level | $29.91 | $82.46 |
| Average True Range (ATR) | 1.20 | 2.94 |
| MACD | -0.06 | 0.24 |
| Stochastic Oscillator | 62.20 | 65.19 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounted for less than 10% of fiscal 2025 total sales. In fiscal 2025, the company wholesaled 181,388 units and generated $9.6 billion in revenue.